Table 1.
Clinico-pathologic features of salivary duct carcinoma.
| SDCDN (N=15) | SDCXPA (N=14) | |
|---|---|---|
| Men | 14 (93%) | 11 (79%) |
| Women | 1 (7%) | 3 (21 %) |
| Age median (range), years | 67 (51-82) | 65 (31-98) |
| Smoking history | 7 (47%) | 9 (64%) |
| Primary site | ||
| Parotid | 15 (100%) | 13 (93%) |
| Submandibular gland | 0 | 1 (7%) |
| Tumor size mean (range), cm | 3.2 (1.7-5.0) | 2.5 (1.1-5.0) |
| AR immunoexpression | 15 (100%) | 14 (100%) |
| Clinical stage | ||
| I | 2 (13%) | 1 (7%) |
| II | 0 | 1 (7%) |
| III | 1 (7%) | 2 (14%) |
| IV | 12 (80%) | 10 (71%) |
| Treatment | ||
| Surgery | 15 (100%) | 14 (100%) |
| RT | 15 (100%) | 13 (93%) |
| CT | 10 (67%) | 7 (50%) |
| Anti-AR | 0 | 2 (14%) |
| Anti-HER2 | 0 | 1 (7%) |
| ALK inhibitor | 1 (7%) | 0 |
| Distant recurrence | ||
| Bone | 5 (33%) | 4 (29%) |
| Lung | 7 (47%) | 2 (14%) |
| Brain | 2 (13%) | 2 (14%) |
| Liver | 0 | 3 (21%) |
| Clinical outcome | ||
| FU period median (range), months | 31 (5-82) | 13 (2-160) |
| Death | 8 (53%) | 6 (43%) |
| Disease-related death | 6 (40%) | 5 (36%) |
| Recurrence | 9 (60%) | 9 (57%) |
Abbreviations: SDC=salivary duct carcinoma, SDCDN=salivary duct carcinoma de novo, SDCXPA=salivary duct carcinoma ex pleomorphic adenoma, AR=androgen receptor, RT=radiation therapy, CT=chemotherapy. CTRT=chemotherapy and radiation therapy, FU=follow up.